vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and KKR Real Estate Finance Trust Inc. (KREF). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $25.8M, roughly 1.3× KKR Real Estate Finance Trust Inc.). KKR Real Estate Finance Trust Inc. runs the higher net margin — -101.7% vs -299.9%, a 198.1% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -26.6%). Over the past eight quarters, Karyopharm Therapeutics Inc.'s revenue compounded faster (1.4% CAGR vs -18.8%).
KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.
KPTI vs KREF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $25.8M |
| Net Profit | $-102.2M | $-26.2M |
| Gross Margin | — | — |
| Operating Margin | -52.4% | -105.1% |
| Net Margin | -299.9% | -101.7% |
| Revenue YoY | 11.6% | -26.6% |
| Net Profit YoY | -232.0% | -229.6% |
| EPS (diluted) | $-7.02 | $-0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $25.8M | ||
| Q3 25 | $44.0M | $25.3M | ||
| Q2 25 | $37.9M | $30.2M | ||
| Q1 25 | $30.0M | $31.3M | ||
| Q4 24 | $30.5M | $35.1M | ||
| Q3 24 | $38.8M | $37.0M | ||
| Q2 24 | $42.8M | $40.4M | ||
| Q1 24 | $33.1M | $39.1M |
| Q4 25 | $-102.2M | $-26.2M | ||
| Q3 25 | $-33.1M | $13.8M | ||
| Q2 25 | $-37.3M | $-29.7M | ||
| Q1 25 | $-23.5M | $-4.9M | ||
| Q4 24 | $-30.8M | $20.3M | ||
| Q3 24 | $-32.1M | $-7.4M | ||
| Q2 24 | $23.8M | $25.8M | ||
| Q1 24 | $-37.4M | $-3.1M |
| Q4 25 | -52.4% | -105.1% | ||
| Q3 25 | -34.6% | 50.4% | ||
| Q2 25 | -64.3% | -101.3% | ||
| Q1 25 | -110.8% | -18.3% | ||
| Q4 24 | -102.4% | 55.8% | ||
| Q3 24 | -67.8% | -19.6% | ||
| Q2 24 | -65.7% | 63.3% | ||
| Q1 24 | -101.9% | -8.7% |
| Q4 25 | -299.9% | -101.7% | ||
| Q3 25 | -75.2% | 54.4% | ||
| Q2 25 | -98.2% | -98.5% | ||
| Q1 25 | -78.2% | -15.5% | ||
| Q4 24 | -100.8% | 57.7% | ||
| Q3 24 | -82.7% | -20.0% | ||
| Q2 24 | 55.6% | 63.9% | ||
| Q1 24 | -112.8% | -7.9% |
| Q4 25 | $-7.02 | $-0.49 | ||
| Q3 25 | $-3.82 | $0.12 | ||
| Q2 25 | $-4.32 | $-0.53 | ||
| Q1 25 | $-2.77 | $-0.15 | ||
| Q4 24 | $-2.33 | $0.22 | ||
| Q3 24 | $-3.85 | $-0.19 | ||
| Q2 24 | $-2.97 | $0.29 | ||
| Q1 24 | $-4.85 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $84.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-292.9M | $1.2B |
| Total Assets | $108.4M | $6.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $84.6M | ||
| Q3 25 | $37.7M | $204.1M | ||
| Q2 25 | $38.7M | $107.7M | ||
| Q1 25 | $38.8M | $106.4M | ||
| Q4 24 | $62.5M | $104.9M | ||
| Q3 24 | $72.8M | $108.8M | ||
| Q2 24 | $84.8M | $107.2M | ||
| Q1 24 | $30.6M | $106.5M |
| Q4 25 | $-292.9M | $1.2B | ||
| Q3 25 | $-269.3M | $1.2B | ||
| Q2 25 | $-238.9M | $1.2B | ||
| Q1 25 | $-205.9M | $1.3B | ||
| Q4 24 | $-186.0M | $1.3B | ||
| Q3 24 | $-159.6M | $1.4B | ||
| Q2 24 | $-132.1M | $1.4B | ||
| Q1 24 | $-169.0M | $1.4B |
| Q4 25 | $108.4M | $6.5B | ||
| Q3 25 | $96.2M | $6.5B | ||
| Q2 25 | $104.9M | $6.8B | ||
| Q1 25 | $127.7M | $6.6B | ||
| Q4 24 | $164.4M | $6.4B | ||
| Q3 24 | $189.5M | $6.8B | ||
| Q2 24 | $214.0M | $7.1B | ||
| Q1 24 | $204.5M | $7.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $72.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $72.3M | ||
| Q3 25 | $-5.9M | $18.5M | ||
| Q2 25 | $-18.7M | $21.1M | ||
| Q1 25 | $-39.0M | $15.9M | ||
| Q4 24 | $-25.8M | $132.6M | ||
| Q3 24 | $-19.5M | $49.1M | ||
| Q2 24 | $-38.5M | $30.6M | ||
| Q1 24 | $-43.7M | $34.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-25.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-43.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -84.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -132.6% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.54× | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.62× | 1.19× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
KREF
Segment breakdown not available.
